江松福

Pola-R-CHP in previously untreated DLBCL with international prognostic index score 0–1: a multicenter real-world retrospective study in China

Abstract Purpose Approximately 30% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) cases are categorized as low-risk by the international prognostic index (IPI). Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has demonstrated e...